United Therapeutics Company Description
United Therapeutics hopes its products will be in vein. Its intravenous drug Remodulin treats pulmonary hypertension, which affects the blood vessels between the heart and lungs; the firm is also investigating Remodulin to improve liver transplant outcomes. Other products in the biotech's pipeline aim to treat cardiovascular disease, as well as various cancers and infectious diseases. In addition to its drug development activities, United Therapeutics' Medicomp unit provides cardiac monitoring services over the phone and Internet using its CardioPAL event monitors, which detect heart arrhythmias and ischemic heart disease.
View the Comprehensive Company Description for United Therapeutics
The Company Description provides a historical perspective of United Therapeutics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of United Therapeutics's evolution in the marketplace.
